Optic pathway glioma
Citation, DOI, disclosures and article data
At the time the article was created Frank Gaillard had no recorded disclosures.View Frank Gaillard's current disclosures
Optic pathway gliomas are relatively uncommon tumors, with a variable clinical course and usually seen in the setting of neurofibromatosis type I (NF1). Histologically the majority are pilocytic astrocytomas.
They are characterized by imaging by an enlarged optic nerve seen either on CT or MRI. Usually showing low T1 and a high central T2 signal on MRI images, enhancement is variable.
These tumors have sometimes been divided into optic pathway gliomas and hypothalamic gliomas (not to be confused with hypothalamic hamartomas). In cases where a tumor is confined to the optic nerves (Dodge stage 1 – see below), they can safely be referred to as optic nerve gliomas. Often, however, they are either centered on or extend to involve the chiasm and optic radiations. In such cases, they are difficult to distinguish from hypothalamic gliomas and such a distinction is in most instances artificial. In such more posterior cases, the term hypothalamic-optochiasmatic glioma is perhaps more accurate although it certainly does not roll off the tongue.
As such, generally, the term optic pathway glioma is favored, recognizing that there may be involvement of the hypothalamus.
Optic pathway gliomas typically present in children, accounting for 10-15% of supratentorial tumors in this age group, and are often in the setting of neurofibromatosis type 1 (NF1) (10-63%) 3. In this setting, the tumors are often low-grade and indolent.
Males and females are approximately equally affected.
In adults, optic nerve gliomas do occur but are very rare and usually aggressive tumors 4. In such cases, no association with NF1 has been found 4.
Clinical presentation varies depending on the extent and location of the tumor.
Decreased vision (63%) 5 is usually evident and can be documented with visual field examination if the child is old enough. In orbital optic nerve gliomas, eventually, mass effects will also occur with proptosis.
Involvement of the hypothalamus may result in polyuria/polydipsia 4, as well as obesity, sexual precocity and endocrine dysfunction (e.g. short stature). Diencephalic symptoms include a change in alertness and hyperactivity.
In large intracranial tumors, symptoms of raised intracranial pressure, focal neurological deficits and hydrocephalus from distortion of the midbrain may also be encountered.
Most optic pathway gliomas are pilocytic astrocytomas (WHO CNS grade 1), although their imaging characteristics are not specific with regard to their histologic features. Varying degrees of cystic change and enhancement are demonstrated. The tumors may appear smooth, fusiform, eccentric, or lobulated.
The most widely accepted classification of optic pathway gliomas is the Dodge classification that was first proposed by Dodge et al. in 1958 8. The Dodge classification divides these tumors into just three groups based on anatomical localization:
stage 1: optic nerves only
stage 2: chiasm involved (with or without optic nerve involvement)
stage 3: hypothalamic involvement and/or other adjacent structures
A more recent modification of the Dodge classification has been proposed which further subdivides each stage 9.
Radiographs no longer have any real role to play in the diagnosis of orbital masses, however, if performed enlargement of the optic canal may be demonstrated if a tumor is not confined to the orbit. Additional findings of neurofibromatosis type 1 may also be visible.
CT is often the first investigation performed and although not as sensitive as MRI, the diagnosis can often be made, especially if thin slice imaging through the orbits is performed, or coronal and sagittal reconstructions obtained from volumetric data.
enlargement of the optic nerve and the mass may either be fusiform or exophytic in appearance.
the optic nerve may be elongated with kinking or buckling 5
MR imaging is optimal for showing the relationship of the mass to the hypothalamus, optic chiasm, and infundibulum as well as the intraorbital and intercanalicular components of the mass. Large tumors are typically heterogeneous with cystic and solid components.
T1: enlargement, often iso to hypointense compared to the contralateral side
thin low-signal at the periphery representing the dura 5
T1 C+ (Gd): enhancement is variable
Treatment and prognosis
These tumors demonstrate variable clinical and radiological progression and therefore require a multi-disciplinary approach. In patients with NF1, it is not unusual for these tumors to be quiescent, with little progression demonstrated over some years. In others, the tumors are more aggressive with extension along the optic pathways 3.
Initial management involves serial MRI scans and visual acuity testing. Treatment is only initiated following disease progression with either reduction in visual acuity or enlargement of tumor on neuroimaging 10.
Management options include surgery, radiotherapy and chemotherapy.
Chemotherapy is the first-line treatment and initially involves treatment with carboplatin and vincristine 12. If this is unsuccessful other regimens can be trialled.
Radiotherapy is associated with an increased risk of secondary central nervous system malignancies and is therefore only used in older children and cases where chemotherapy has failed to halt the progression of the disease 10.
Surgery is rarely curative, as the borders of the tumor tend to extend beyond MRI findings. Surgery invariably leads to visual loss, endocrine deficits and cerebrovascular accidents. It is therefore reserved for cases with minimal visual potential, severe disfiguring proptosis or corneal exposure 10, 11.
Overall optic pathway gliomas carry a 5-year survival rate of >90% 12.
The absence of calcification can be used to differentiate optic nerve glioma from optic nerve sheath meningioma 6.
Additionally, when the bulk of a tumor is located at the chiasm, the differential should include pituitary region masses.
- 1. Kanamalla US. The optic nerve tram-track sign. Radiology. 2003;227 (3): 718-9. doi:10.1148/radiol.2273010758 - Pubmed citation
- 2. Hendrix LE, Kneeland JB, Haughton VM et-al. MR imaging of optic nerve lesions: value of gadopentetate dimeglumine and fat-suppression technique. AJR Am J Roentgenol. 1990;155 (4): 849-54. AJR Am J Roentgenol (abstract) - Pubmed citation
- 3. Wright JE, Mcdonald WI, Call NB. Management of optic nerve gliomas. Br J Ophthalmol. 1980;64 (8): 545-52. Br J Ophthalmol (link) - Free text at pubmed - Pubmed citation
- 4. Millar WS, Tartaglino LM, Sergott RC et-al. MR of malignant optic glioma of adulthood. AJNR Am J Neuroradiol. 1995;16 (8): 1673-6. AJNR Am J Neuroradiol (abstract) - Pubmed citation
- 5. Müller-Forell WS, Boltshauser E. Imaging of Orbital and Visual Pathway Pathology. Springer Verlag. (2005) ISBN:3540279881. Read it at Google Books - Find it at Amazon
- 6. Sutton D. Textbook of Radiology and Imaging. Churchill Livingstone. (2003) ISBN:0443071098. Read it at Google Books - Find it at Amazon
- 7. Peter C. Burger, Bernd W. Scheithauer. Tumors of the Central Nervous System. ISBN: 9781933477015
- 8. Dodge HW, Love JG, Craig WM, Dockerty MB, Kearns TP, Holman CB, Hayles AB. Gliomas of the optic nerves. A.M.A. archives of neurology and psychiatry. 79 (6): 607-21. Pubmed
- 9. Taylor T, Jaspan T, Milano G, Gregson R, Parker T, Ritzmann T, Benson C, Walker D. Radiological classification of optic pathway gliomas: experience of a modified functional classification system. The British journal of radiology. 81 (970): 761-6. doi:10.1259/bjr/65246351 - Pubmed
- 10. Fried I, Tabori U, Tihan T, Reginald A, Bouffet E. Optic Pathway Gliomas: A Review. CNS Oncol. 2013;2(2):143-59. doi:10.2217/cns.12.47 - Pubmed
- 11. Spicer G, Kazim M, Glass L et al. Accuracy of MRI in Defining Tumor-Free Margin in Optic Nerve Glioma Surgery. Ophthalmic Plast Reconstr Surg. 2013;29(4):277-80. doi:10.1097/IOP.0b013e318291658e - Pubmed
- 12. Nicolin G, Parkin P, Mabbott D et al. Natural History and Outcome of Optic Pathway Gliomas in Children. Pediatr Blood Cancer. 2009;53(7):1231-7. doi:10.1002/pbc.22198 - Pubmed